A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: lined (742)

Dr Mayank Patel publications list 2019

Description
Dr Mayank Patel: publications Leaflets and articles  ‘Managing diabetes when you are ill’, a new, updated leaflet for Diabetes Research and
Url
/Media/UHS-website-2019/Docs/Consultant-publications-lists/Dr-Mayank-Patel-publications-list-2019.pdf

New data protection laws (GDPR) come into effect

Description
New data protection laws designed to give individuals more control over how organisations use their personal information come into force today
Url
/AboutTheTrust/Newsandpublications/Latestnews/2018/May-2018/New-data-protection-laws-GDPR-come-into-effect.aspx

Laser safety training - typical course programme

Description
Laser safety training - typical course programme9am 9.30am Registration, tea and coffee Basics of lasers and intense light sources Terminology, characteristic
Url
/Media/UHS-website-2019/Docs/Medical-physics/Laser-safety-training-typical-course-programme.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description
Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuximab-Dexamethasone (40)-Pomalidomide Indication • Isatuximab is indicated where; - the patient has
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

Papers Trust Board - 30 January 2020

Description
Date Time Location Chair Apologies Agenda Trust Board – Open Session 30/01/2020 9:00 - 11:45 Conference Room, Heartbeat Education
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2020/Papers-Trust-Board-30-January-2020.pdf

Daratumumab

Description
Chemotherapy Protocol Myeloma Daratumumab Regimen • Myeloma – Daratumumab monotherapy Indication • Daratumumab monotherapy is recommended as an option for treating relapsed and refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab.pdf

DVd_Twice weekly_Daratumumab-Bortezomib-Dexamethasone_Cycles 1 to 8

Description
Chemotherapy Protocol Myeloma DVd (twice weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (twice weekly)-Daratumumab-Dexamethasone Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Twice-weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone Cycles 1 to 8

Description
Chemotherapy Protocol Myeloma DVd (Weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (weekly)-Daratumumab-Dexamethasone Indication • Daratumumab in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

Vinorelbine PO (day 1, 8, 15) Ver 1.2

Description
Chemotherapy Protocol BREAST CANCER VINORELBINE Oral (Day 1, 8, 15) Regimen Breast Cancer – Vinorelbine Oral (day 1, 8, 15) Indication Treatment
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Vinorelbine-PO-day-1-8-15-Ver-1.2.pdf

Food labelling - patient information

Description
This factsheet contains information about food labelling laws in the UK and describes the meaning of 'may contain traces' food labels
Url
/Media/UHS-website-2019/Patientinformation/Childhealth/Foodlabelling-930-PIL.pdf
51 to 60 of 587
Previous … 4 5 6 7 8 … Next